Immune-Derived PD-L1 gene expression defines a subgroup of stage II/III colorectal cancer patients with favorable prognosis who may be harmed by adjuvant chemotherapy

Cancer Immunology Research

Volumn 4, Issue 7, 2016, Pages 582-591

  Dunne, Philip D ^a   McArt, Darragh G ^a   O'reilly, Paul G ^a   Coleman, Helen G ^a   Allen, Wendy L ^a   Loughrey, Maurice ^a,b   Van Schaeybroeck, Sandra ^a   McDade, Simon ^a   Salto Tellez, Manuel ^a   Longley, Daniel B ^a   Lawler, Mark ^a   Johnston, Patrick G ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PROGRAMMED DEATH 1 LIGAND 1;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; EARLY CANCER; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; PROTEIN TARGETING; RECURRENCE FREE SURVIVAL; ADJUVANT CHEMOTHERAPY; CLUSTER ANALYSIS; COLORECTAL TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; NUCLEIC ACID DATABASE; PATHOLOGY; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; B7-H1 ANTIGEN; CHEMOTHERAPY, ADJUVANT; CLUSTER ANALYSIS; COLORECTAL NEOPLASMS; DATABASES, NUCLEIC ACID; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84979737406     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0302     Document Type: Article

References (20)

1. Jass JR, Morson BC. Reporting colorectal cancer. J Clin Pathol 1987;40: 1016-23.
2. Calon A, Lonardo E, Berenguer-Llergo A, Espinet E, Hernando-Momblona X, Iglesias M, et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet 2015;47:320-9.
3. Isella C, Terrasi A, Bellomo SE, Petti C, Galatola G, Muratore A, et al. Stromal contribution to the colorectal cancer transcriptome. Nat Genet 2015;47:312-9.
4. Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 2015;5:43-51.
5. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014;20:5064-74.
6. Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkanen L, Mecklin JP, et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993;260:812-6.
7. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993;260:816-9.
8. Saeterdal I, Bjorheim J, Lislerud K, Gjertsen MK, Bukholm IK, Olsen OC, et al. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci U S A 2001;98:13255-60.
9. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010;138:2073-87.e3.
10. Carethers JM, Chauhan DP, Fink D, Nebel S, Bresalier RS, Howell SB, et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 1999;117:123-31.
11. Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000;355:1745-50.
12. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015;33:1974-82.
13. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372:2509-20.
14. Bach EA, Aguet M, Schreiber RD. The IFN gamma receptor: A paradigm for cytokine receptor signaling. Annu Rev Immunol 1997;15: 563-91.
15. Des Guetz G, Schischmanoff O, Nicolas P, Perret GY, Morere JF, Uzzan B. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta- Analysis. Eur J Cancer 2009;45:1890-6.
16. Lawler M, Kaplan R, Wilson RH, Maughan TS-CORT Consortium. Changing the paradigm-multistage multiarm randomized trials and stratified cancer medicine. Oncologist 2015;20:849-51.
17. Schneider D, Bianchini G, Horgan D, Michiels S, Witjes W, Hills R, et al. Establishing the evidence bar for molecular diagnostics in personalised cancer care. Public Health Genomics 2015;18:349-58.
18. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3:991-8.
19. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007; 450:903-7.
20. Mitchell MS, DeConti RC. Immunosuppression by 5-fluorouracil. Cancer 1970;26:884-9.